Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168
-TQS-168 was well tolerated and demonstrated excellent pharmacokinetic properties-
-Tranquis plans to start a Phase 2 trial in ALS by the end of 2022-
Excerpt from the Press Release:
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced the completion of its Phase 1 clinical trial of TQS-168, a small molecule modulator of PGC-1a in development for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Single and multiple doses of TQS-168 were well tolerated in 78 healthy volunteers, and no serious adverse events were reported. Adverse events were mild, transient, and did not lead to treatment discontinuation. TQS-168 also demonstrated excellent pharmacokinetic properties with adequate plasma exposures. Based on these results, Tranquis plans to initiate a Phase 2 clinical trial of TQS-168 in ALS by the end of the year.
“The data from our Phase 1 study of TQS-168 demonstrate that target plasma exposures can be achieved at dose levels that are well tolerated. The ability to reach human exposures that were associated with benefits in preclinical models of ALS bolsters our confidence in Tranquis’ approach. We are developing an orally administered compound that targets PGC-1a in myeloid cells to treat neurodegenerative diseases in which dysfunctional myeloid cells play a key role in disease progression,” said Jonas Hannestad, MD, PhD, Chief Medical Officer at Tranquis. “By the end of the year, we plan to advance TQS-168 into a Phase 2 study in people living with ALS, a devastating disease with high unmet need.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?